160 related articles for article (PubMed ID: 37652513)
1. Pembrolizumab Monotherapy
Matsuo M; Masuda M; Yamauchi M; Taura M; Hashimoto K; Kogo R; Jiromaru R; Hongo T; Manako T; Nakagawa T
In Vivo; 2023; 37(5):2188-2196. PubMed ID: 37652513
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study.
Cohen EEW; Soulières D; Le Tourneau C; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Zhang P; Cheng J; Swaby RF; Harrington KJ;
Lancet; 2019 Jan; 393(10167):156-167. PubMed ID: 30509740
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of pembrolizumab for the first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma in the United States.
Borse RH; Ramakrishnan K; Gandhi J; Dhankhar P; Chirovsky D
J Med Econ; 2022; 25(1):954-965. PubMed ID: 35765888
[TBL] [Abstract][Full Text] [Related]
4. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B; Harrington KJ; Greil R; Soulières D; Tahara M; de Castro G; Psyrri A; Basté N; Neupane P; Bratland Å; Fuereder T; Hughes BGM; Mesía R; Ngamphaiboon N; Rordorf T; Wan Ishak WZ; Hong RL; González Mendoza R; Roy A; Zhang Y; Gumuscu B; Cheng JD; Jin F; Rischin D;
Lancet; 2019 Nov; 394(10212):1915-1928. PubMed ID: 31679945
[TBL] [Abstract][Full Text] [Related]
5. Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.
Taylor MH; Betts CB; Maloney L; Nadler E; Algazi A; Guarino MJ; Nemunaitis J; Jimeno A; Patel P; Munugalavadla V; Tao L; Adkins D; Goldschmidt JH; Cohen EEW; Coussens LM
Clin Cancer Res; 2022 Mar; 28(5):903-914. PubMed ID: 34862248
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Pembrolizumab Regimens for the First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma in Argentina.
Wurcel V; Chirovsky D; Borse R; Altuna JI; Carabajal F; Gandhi J
Adv Ther; 2021 May; 38(5):2613-2630. PubMed ID: 33855690
[TBL] [Abstract][Full Text] [Related]
7. The UK Divide: Does Having a Pembrolizumab-Chemotherapy Option in Head and Neck Cancer Matter? Real-world Experience of First-line Palliative Pembrolizumab Monotherapy and Pembrolizumab-Chemotherapy Combination in Scotland.
Thapa A; Cowell A; Peters A; Noble DJ; James A; Lamb C; Grose D; Vohra S; Schipani S; Mactier K; Mackenzie J; Srinivasan D; Laws K; Moleron R; Niblock P; Soh FY; Paterson C; Wilson C
Clin Oncol (R Coll Radiol); 2024 May; 36(5):287-299. PubMed ID: 38395634
[TBL] [Abstract][Full Text] [Related]
8. Survival impact of sequential chemotherapy following pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma.
Iwaki S; Kadowaki S; Honda K; Narita Y; Masuishi T; Taniguchi H; Ando M; Muro K; Sawabe M; Suzuki H; Nishikawa D; Beppu S; Terada H; Kishikawa T; Kawakita D; Hanai N
Int J Clin Oncol; 2024 Jun; 29(6):764-770. PubMed ID: 38555323
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab with or without chemotherapy versus cetuximab plus chemotherapy to treat recurrent or metastatic head and neck squamous cell carcinoma: An updated KEYNOTE-048 based cost-effectiveness analysis.
She L; Tian K; Han J; Zuo W; Wang Z; Zhang N
Oral Oncol; 2022 Jun; 129():105871. PubMed ID: 35483156
[TBL] [Abstract][Full Text] [Related]
10. Real-world Therapeutic Outcomes of the Pembrolizumab Regimen as First-line Therapy for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: A Single-center Retrospective Cohort Study in Japan.
Sano D; Tokuhisa M; Takahashi H; Hatano T; Nishimura G; Ichikawa Y; Oridate N
Anticancer Res; 2022 Sep; 42(9):4477-4484. PubMed ID: 36039457
[TBL] [Abstract][Full Text] [Related]
11. Pembrolizumab vs the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: A Cost-Effectiveness Analysis.
Lang Y; Dong D; Wu B
Clin Drug Investig; 2020 Dec; 40(12):1137-1146. PubMed ID: 33095408
[TBL] [Abstract][Full Text] [Related]
12. Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients.
Li L; Chen L; Yan L; Guo Y; Li F; Fan M; Lan M; Lai X; Zhou J; Huang Y; Xu P; Lang J; Feng M
Radiat Oncol; 2023 Jul; 18(1):109. PubMed ID: 37403098
[TBL] [Abstract][Full Text] [Related]
13. Rationale and design of LUX-Head & Neck 1: a randomised, Phase III trial of afatinib versus methotrexate in patients with recurrent and/or metastatic head and neck squamous cell carcinoma who progressed after platinum-based therapy.
Machiels JP; Licitra LF; Haddad RI; Tahara M; Cohen EE
BMC Cancer; 2014 Jun; 14():473. PubMed ID: 24973959
[TBL] [Abstract][Full Text] [Related]
14. Talimogene Laherparepvec and Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (MASTERKEY-232): A Multicenter, Phase 1b Study.
Harrington KJ; Kong A; Mach N; Chesney JA; Fernandez BC; Rischin D; Cohen EEW; Radcliffe HS; Gumuscu B; Cheng J; Snyder W; Siu LL
Clin Cancer Res; 2020 Oct; 26(19):5153-5161. PubMed ID: 32669371
[TBL] [Abstract][Full Text] [Related]
15. First-line pembrolizumab ± chemotherapy for recurrent/metastatic head and neck cancer: Japanese subgroup of KEYNOTE-048.
Takahashi S; Oridate N; Tanaka K; Shimizu Y; Fujimoto Y; Matsumoto K; Yokota T; Yamazaki T; Takahashi M; Ueda T; Hanai N; Yamaguchi H; Hara H; Yoshizaki T; Yasumatsu R; Nakayama M; Shiga K; Fujii T; Mitsugi K; Takahashi K; Nohata N; Gumuscu B; Swaby RF; Tahara M
Int J Clin Oncol; 2022 Dec; 27(12):1805-1817. PubMed ID: 36264378
[TBL] [Abstract][Full Text] [Related]
16. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial.
Seiwert TY; Burtness B; Mehra R; Weiss J; Berger R; Eder JP; Heath K; McClanahan T; Lunceford J; Gause C; Cheng JD; Chow LQ
Lancet Oncol; 2016 Jul; 17(7):956-965. PubMed ID: 27247226
[TBL] [Abstract][Full Text] [Related]
17. Pembrolizumab versus methotrexate, docetaxel, or cetuximab in recurrent or metastatic head and neck squamous cell carcinoma (KEYNOTE-040): Subgroup analysis by pattern of disease recurrence.
Harrington KJ; Cohen EEW; Soulières D; Dinis J; Licitra L; Ahn MJ; Soria A; Machiels JP; Mach N; Mehra R; Burtness B; Swaby RF; Lin J; Ge J; Lerman N; Tourneau CL
Oral Oncol; 2023 Dec; 147():106587. PubMed ID: 37925894
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab in the first-line treatment of advanced head and neck cancer.
de Sousa LG; Ferrarotto R
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1321-1331. PubMed ID: 34689660
[TBL] [Abstract][Full Text] [Related]
19. Safety evaluation of pembrolizumab for treating recurrent head and neck squamous cell carcinoma.
Desilets A; Soulières D
Expert Opin Drug Saf; 2020 Aug; 19(8):927-934. PubMed ID: 32458764
[TBL] [Abstract][Full Text] [Related]
20. Real-world Data Study of the Efficacy and Toxicity of Nivolumab
Macia-Rivas L; Fernandez-Laguna CL; Alvarez-Asteinza C; Maray I; Carbajales-Alvarez M; Lozano-Blazquez A
Anticancer Res; 2023 Apr; 43(4):1681-1688. PubMed ID: 36974777
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
